Written questions by Fortune.

Communities and Local Government, with reference to paragraph 2.2.5 of the English Devolution White Paper, published on 16 December 2024, whether he plans to amend the Greater London Authority's powers.

The Greater London Authority (GLA) is an Established Mayoral Strategic Authority (EMSA) and will be formally made as such via the English Devolution and Community Empowerment Bill (‘the Bill’). As with other EMSAs, the Bill will grant the GLA the ‘right to request’, allowing them to request additions to the devolution framework to help deliver their areas of competence. Requests could be for further powers, funding or place-based pilots. Requests will be considered by Government and responded to within 6 months. This will be the primary way the powers of all Strategic Authorities will be amended going forward; however the Bill delivers on our commitment to devolve responsibility for the disposal of TfL operational land to the Mayor of London. It is my Department’s expectation that some of the GLA’s requests for future devolved functions will be informed by an analysis of the powers and policy approaches of any global cities which can provide valuable lessons for London. As such, there is no defined list of global city authorities with which the Department plans to compare to London. The working group jointly sponsored by my Department and the GLA has met a total of three times since November 2024. It has provided a forum to discuss potential priorities for the GLA’s ‘right to request’ informed by global city comparisons. The group has also worked to ensure the Bill's provisions align with the GLA's unique devolution settlement. Work has also been ongoing to agree an Integrated Settlement for London, as was announced at the Spending Review in June 2025. The working group is intended to provide a forum for engagement with the GLA on an ongoing basis, as such the Department does not plan to publish final conclusions.

What assessment he has made of the potential implications for his policies of the Metropolitan Police's decision to withdraw police liaison officers from magistrates' courts in London.

Police Liaison Officers have for many years played an important role in the daily operations of our London courts. Conversations are ongoing between HMCTS and the Police to understand the implications of the decision to withdraw them.

What assessment she has made of potential impact of increasing the Dart Charge on the number of daily crossings.

Initial assessments suggest fewer car journeys and more goods vehicle journeys will be made than would have been the case if charges had been left unchanged. Revenue from the charging scheme, net of costs, must be spent on transport projects.

Whether his Department has a target of number of registered patients per GP.

Each general practice is required to provide services to meet the reasonable needs of their patients. There is no NHS England recommendation for how many patients a general practitioner (GP) should have assigned, or the ratio of GPs or other practice staff to patients. The demands each patient places on their general practice are different and can be affected by many different factors, including rurality and patient demographics. It is necessary to consider the workforce for each practice as a whole; not only GPs but also the range of health professionals available who are able to respond to the needs of their patients.

What steps she is taking to reduce public spending on Southeastern Railway.

The Government is busy delivering on its plan to overhaul the railways through the creation of Great British Railways, uniting train and track with the focus of delivering for passengers and freight. In June this year, Southeastern and Network Rail Kent route united under a single leadership team known as South Eastern Railway – a significant step towards the creation of Great British Railways. This more collaborative approach is resulting in greater efficiency with better, faster decisions for customers and taxpayers, and reducing the subsidy required to operate Southeastern.

Communities and Local Government, what assessment he has made of the potential merits of introducing simple majority voting in the London Assembly.

The London Assembly is a unique institution in the English Devolution landscape, responsible for scrutiny rather than executive decision-making. It has successfully served the people of London for the last 25 years and will continue to act as the body responsible for scrutinising the Mayor of London.The government will engage with both the Mayor of London and the London Assembly on proposals for improving accountability and scrutiny as set out in the English Devolution White Paper. However, the government has no plans to change voting arrangements in the London Assembly.

What assessment she has made of the potential impact of the proposed Bakerloo Line extension to the London Borough of Bromley on Southeastern rail services in Hayes.

We recognise the socio-economic benefits that the proposed Bakerloo Line Extension could offer regionally and nationally, and we want to improve transport and services for passengers. As transport in London is devolved to the Mayor of London and Transport for London, it is for them to make decisions on the merits of investment including any upgrade to the Bakerloo Line.

What her policy is on investment in the Dartford Crossing.

The Dartford Crossing is one of the most important roads in the UK, used by an average of 150,000 vehicles daily, of which almost 40% are freight vehicles: a much higher proportion than for other major roads. Consequently, significant annual expenditure (£42.2million in 2023/24) goes on operating, maintaining and improving the Crossing, particularly in relation to the older tunnels, which require increasingly intensive maintenance to, for example, the ventilation, electrical and drainage systems.Additional capacity across the River Thames east of London will be provided by the Lower Thames Crossing, complementing the Dartford Crossing which will remain an essential part of the London Orbital road.

What steps he is taking to help ensure areas with high levels of housebuilding have adequate GP capacity.

The National Health Service has a statutory duty to ensure there are sufficient medical services, including general practice (GP), in each local area. It should take account of population growth and demographic changes. Integrated care boards are responsible for commissioning, namely planning, securing, and monitoring, GP services within their health systems through delegated responsibility from NHS England. Local planning authorities are responsible for negotiating and agreeing developer contributions to support necessary associated infrastructure when new housing developments are built, including GP practices. At a national level, we continue to work closely with the Ministry of Housing, Communities and Local Government to ensure all new and existing developments have an adequate level of healthcare infrastructure for the community.

Communities and Local Government, what steps he is taking to build more family homes in London and the South East.

The government’s Plan for Change includes a hugely ambitious milestone of building 1.5 million safe and decent homes in England in this Parliament. Through bold reform of the planning system; significant investment in land, infrastructure, and social and affordable housing; and a range of other measures, we will deliver the homes working families need across the country, including in London and the South-East.

Communities and Local Government, if he will take steps to protect family homes from being converted into houses in multiple occupation.

National permitted development rights allow a C3 dwellinghouse to change use to a C4 House in Multiple Occupation for up to six people sharing facilities without the need for a planning application. Larger Houses in Multiple Occupation require a planning application which the local authority will determine in-line with the local plan and in consultation with neighbours. Local authorities can remove the permitted development right for HMOs of up to 6 people to protect local amenity or wellbeing of the area by introducing an ‘Article 4’ direction.

Communities and Local Government, what his plans are for the future of Business Improvement Districts.

The Government recognises the important role Business Improvement Districts (BIDs) can play in regeneration and place making. We encourage BIDs to work in partnership with their local authority to deliver growth in their local area. We made a commitment to strengthen BIDs and raise standards in the English Devolution White Paper in December 2024 and we are considering options for reform.

What steps he plans to take to increase the number of GPs in South East London.

The Government committed to recruiting over 1,000 recently qualified general practitioners (GPs) in primary care networks (PCNs) through an £82 million boost to the Additional Roles Reimbursement Scheme (ARRS) over 2024/25, as part of an initiative to secure the future pipeline of GPs. This funding has been continued into 2025/26.Data on the number of recently qualified GPs for which PCNs are claiming reimbursement via the ARRS show that since 1 October 2024, over 2,000 GPs were recruited through the scheme. Several changes have been made to increase the flexibility of the ARRS in 2025/26. This includes GPs and practice nurses included in the main ARRS funding pot, an uplift of the maximum reimbursable rate for GPs in the scheme, and no caps on the number of GPs that can be employed through the scheme.Thanks to new flexibilities under the ARRS, South East London general practices have grown the number of GPs across South East London by approximately 40 working time equivalent between July 2024 and July 2025, utilising the funding offered through this scheme to bring South East London in line with the London average of GPs per 10,000 registered population.NHS South East London has work programmes in place to improve recruitment and retention and has commissioned a package of recruitment and retention support from the South East London Workforce Development Hub, a training hub for general practice.We are investing an additional £1,092 million in general practice to reinforce the front door of the National Health Service, bringing total spend on the GP Contract to £13.4 billion in 2025/26. This is the biggest increase in over a decade. The 8.9% boost to the GP contract in 2025/26 is faster than the 5.8% growth to the NHS budget overall.

What steps she has taken to encourage bus and train operators to reduce levels of disability hate crime on their services.

The government believes that everyone should be able to make journeys on public transport services without fearing that they will become a victim of crime. It is especially concerning that people should experience disability hate crime whilst using buses and trains, and operators must do all they can to challenge such unacceptable behaviour in partnership with relevant authorities. We introduced the Bus Services (No.2) Bill which focuses on delivering safe, more reliable bus networks. The Bill sets requirements for mandatory training on how to recognise and respond appropriately to incidents of criminal and anti-social behaviour, on buses for staff, including drivers and those who deal directly with the travelling public or with issues related to the travelling public. This Bill will also extend requirements for relevant bus staff to undertake training relating to disabled passengers.Provisions in the Bus Services (No 2) Bill would also give all local transport authorities the power to make bus byelaws, which can be enforced by local authority officers on vehicles and at bus stations and stops. This, combined with targeted enforcement, should lead to safer networks. Transport Safety Officers or Transport Safety and Enforcement Officers are also already operating in some areas, including those participating in the Department’s Tackling Anti-Social Behaviour on Transport pilots. The British Transport Police (BTP) are responsible for policing the rail network in England, Scotland and Wales. They take any reports of crime seriously, including disability hate crimes. The BTP works closely with the rail industry, including train operators, to target offenders across the network and ensure it remains a safe environment for passengers and rail staff. The BTP encourage crime to be reported via it is 61016 text number or in an emergency to call 999.

Innovation and Technology, how much funding the Government provided for research into actinic keratosis in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into hidradenitis suppurativa in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into melanoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into squamous cell carcinoma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into scleroderma in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.

Innovation and Technology, how much funding the Government provided for research into pemphigus in the 2023-24 financial year; and which public bodies provided that funding.

The Department of Health and Social Care (DHSC) invests £1.5 billion per year on health research through the National Institute for Health and Care Research (NIHR). The NIHR supports and delivers research in the following many aspects skin and dermatological conditions including linking genetic research and personalised medicine with common skin diseases such as acne, drug reactions, eczema, and psoriasis and skin cancers including melanoma, squamous cell carcinoma and basal cell carcinoma. It also supports research into skin infections such as herpes simplex, fungal infections, impetigo and cellulitis along with children’s skin disorders and rare skin diseases. UKRI delivers a substantial portfolio of researcher-led projects and strategic investments. Dermatology research supported by MRC covers the breadth of skin and skin associated diseases including inflammatory skin disease, atopic dermatitis (eczema) and skin cancer research. This includes basic biological mechanisms of disease to early-stage interventions such as diagnostics and treatment development. In addition to the individual awards stated below, MRC supports other active research grants in the noted areas through strategic awards made to MRC Research Units.- The Translational skin immunology programme at the MRC Translational Immune Discovery Unit at the University of Oxford investigates the role of T-cells in Inflammatory skin diseases such as psoriasis.- The Translational Melanoma Research Group from the MRC Human Genetics Unit at the University of Edinburgh is investigating the mechanisms of melanoma development & drug resistance through their programme Targeting developmental cell states in melanoma Details of UKRI and NIHR funding on specific areas is provided in the table below: NIHRUKRIAcneNIHR allocated £2,148,574.06 for research concerning acne research in 2023-24.UKRI did not commit any specific funding for acne research in 2023-24.AlopeciaNIHR did not allocate any funds for research concerning alopecia research during 2023-24UKRI have committed £215,666 for alopecia research for a 3 year period commencing March 2024.PsoriasisNIHR allocated £858,946.12 for research concerning psoriasis research in 2023-24.UKRI have committed £300, 266 for psoriasis research for a 3 year period commencing February 2024 .PemphigusNIHR did not allocate any funds for research concerning pemphigus research during 2023-24UKRI did not commit any specific funding for pemphigus research in 2023-24.Atopic DermatitisNIHR allocated £2,045,996 for research concerning atopic dermatitis research in 2023-24.UKRI have committed £404,880 for atopic dermatitis research for a 3 year period commencing June 2023.Epidermolysis BullosaNIHR did not allocate any funds for research concerning epidermolysis bullosa research during 2023-24UKRI did not commit any specific funding for epidermolysis bullosa research in 2023-24.Hidradenitis SuppurativaNIHR has not allocated any funds for research concerning hidradenitis suppurativa research during 2023-24UKRI did not commit any specific funding for hidradenitis suppurativa research in 2023-24.SclerodermaNIHR allocated £155,575 for research concerning scleroderma research in 2023-24.UKRI did not commit any specific funding for scleroderma research in 2023-24.RosaceaNIHR did not allocate any funds concerning rosacea research during 2023-24UKRI did not commit any specific funding for rosacea research in 2023-24.VitiligoNIHR did not allocate any funds for research concerning vitiligo research during 2023-24UKRI did not commit any specific funding for vitiligo research in 2023-24.Basal Cell CarcinomaNIHR did not allocate any funds concerning basal cell carcinoma research during 2023-24UKRI did not commit any specific funding for basal cell carcinoma research in 2023-24.Squamous Cell CarcinomaNIHR allocated £1,467,858 for research concerning squamous cell carcinoma research in 2023-24UKRI did not commit any specific funding for squamous cell carcinoma research in 2023-24.MelanomaNIHR allocated £1,167,536 for research concerning melanoma research in 2023-24UKRI have committed £176,114 for melanoma research between March 24 and August 25.Actinic KeratosisNIHR did not allocate any funds concerning actinic keratosis research during 2023-24UKRI did not commit any specific funding for actinic keratosis research in 2023-24.